Title : Functional connectivity and cognitive changes after donepezil treatment in healthy participants - Peran_2021_Psychopharmacology.(Berl)__ |
Author(s) : Peran P , Salabert AS , Dondaine T , Leclerc X , Gros-Dagnac H , Ranjeva JP , Lopes R , Lanteaume L , Blin O , Thalamas C , Bordet R , Payoux P |
Ref : Psychopharmacology (Berl) , : , 2021 |
Abstract :
RATIONALE: Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated. OBJECTIVES: The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers. METHODS: The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design. RESULTS: Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition. CONCLUSIONS: In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo. |
PubMedSearch : Peran_2021_Psychopharmacology.(Berl)__ |
PubMedID: 34370064 |
Peran P, Salabert AS, Dondaine T, Leclerc X, Gros-Dagnac H, Ranjeva JP, Lopes R, Lanteaume L, Blin O, Thalamas C, Bordet R, Payoux P (2021)
Functional connectivity and cognitive changes after donepezil treatment in healthy participants
Psychopharmacology (Berl)
:
Peran P, Salabert AS, Dondaine T, Leclerc X, Gros-Dagnac H, Ranjeva JP, Lopes R, Lanteaume L, Blin O, Thalamas C, Bordet R, Payoux P (2021)
Psychopharmacology (Berl)
: